glp-1 class action Mechanisms of of GLP-1RA Insulin, GLP-1 makers to face
Description
In certain clinical trials, when compared to a placebo, patients who used Wegovy lost about 15% of their starting body weight in the first 1 to 1.5 years, Zepbound medication users lost 16%, Foundayo medication users lost 12.4%, and Saxenda users lost 5%
Common injection sites include the abdomen, upper arms, and front of the thighs
It is strategic
2), with the complete dataset cataloged in Supplementary Table 4
